In male mice, THC-driven hyperlocomotion depends on CB1 signaling
Psychotomimetic Cannabinoid Hyperlocomotion Involves GSK-3β Signaling at Striatopallidal Neurons in Male Mice.
AI Summary
This abstract-based summary covers a laboratory study asking how THC causes psychotomimetic-like hyperlocomotion. Researchers used pharmacological and genetic manipulations in cultured cells and adult male mice, testing a low dose of THC (0.3 mg/kg) and measuring locomotor activity. The reported behavioral effect depended on CB1 receptors on dopamine D2 receptor-positive striatopallidal neurons and on signaling involving β-arrestin 1, Akt, and GSK-3β.
The study also reports that pregnenolone and its clinically developed analog AEF0117, described as signaling-specific CB1 receptor inhibitors, prevented THC-induced, GSK-3β-dependent psychomotor stimulation in mice. The findings identify a possible cellular mechanism and research lead, but they do not establish a treatment for psychosis or show that the same mechanism or effects occur in people. The work was conducted in male mice and cultured cells; this abstract-based summary cannot assess details beyond what the abstract reports.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More THC research papers you might find interesting.
Small lab study finds cannabis affected simulated driving and confidence
A lab method measures 17 cannabinoids across five hemp product types
A single-center study finds varied care and no recurrence in follow-up
Explore More Research
Stay informed about the latest cannabis science.